Logo

Howard Robin, Barry Greene, Philip Padou

Jan 11, 2007
Premium
Nektar Therapeutics said this week that it has named Howard Robin as its new president and CEO, effective Jan. 15.
 
Robin currently serves as president and CEO of Sirna Therapeutics, which was acquired by Merck for $1.1 billion in cash (see RNAi News, 1/4/2007).
 
Prior to heading up Sirna, Robin was corporate vice president and general manager of Berlex Laboratories’ US therapeutics division.
 
 
Acorda Therapeutics said this week that it has appointed Barry Greene to its board of directors.
 
Greene is currently the COO of Alnylam Pharmaceuticals.
 
 
Bio-Rad said last week that Philip Padou, one of the company’s directors, has died at the age of 72.
 
Padou had sat on Bio-Rad’s board since 1980. The company said it plans to seek a replacement.

Filed under

Gene Editing, Gene Silencing, & CRISPR
RNAi
Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.